Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | President-Protein Sciences | November 12, 2021 | November 16, 2021 |
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date November 12, 2021 · Filed November 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,117 |
Ending reported balance
After 2021-11-16 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2021-11-12 · Exercise / conversion · Acquired 27,159 · Balance 28,477 Row 2 · 2021-11-12 · Sale · Disposed 700 · Balance 27,777 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2021-11-12 · Sale · Disposed 200 · Balance 27,577 Row 4 · 2021-11-12 · Sale · Disposed 300 · Balance 27,277 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2021-11-12 · Sale · Disposed 537 · Balance 26,740 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2021-11-12 · Sale · Disposed 400 · Balance 26,340 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2021-11-12 · Sale · Disposed 4,054 · Balance 22,286 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 8 · 2021-11-12 · Sale · Disposed 9,043 · Balance 13,243 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 9 · 2021-11-12 · Sale · Disposed 8,989 · Balance 4,254 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 10 · 2021-11-12 · Sale · Disposed 2,535 · Balance 1,719 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 11 · 2021-11-12 · Sale · Disposed 401 · Balance 1,318 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 12 · 2021-11-16 · Exercise / conversion · Acquired 799 · Balance 2,117 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 799 |
Reported balance
After 2021-11-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-12 · Exercise / conversion · Disposed 27,159 · Balance 799 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 0 |
Reported balance
After 2021-11-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-11-16 · Exercise / conversion · Disposed 799 · Balance 0 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.32 · Expires 2025-08-08 | Direct | 13,550 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 13,550 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.32 · Expires 2025-08-08 | Direct | 18,066 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 18,066 F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.41 · Expires 2026-08-07 | Direct | 15,948 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 15,948 F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.41 · Expires 2026-08-07 | Direct | 21,265 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 21,265 F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 11,488 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 11,488 F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 15,318 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 15,318 F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 24,975 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 24,975 F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 24,975 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 24,975 F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $481.82 · Expires 2028-08-06 | Direct | 6,080 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · Balance 6,080 F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $481.82 · Expires 2028-08-06 | Direct | 8,107 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · Balance 8,107 F20: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,151 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 3,151 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,575 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 2,575 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,556 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 1,556 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F11: Fully exercisable.
F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F20: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.
Marker Therapeutics, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 84,411 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 84,411 · Balance 84,411 F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 137,330 |
Reported balance
After 2025-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-17 · Grant · Acquired 137,330 · Balance 137,330 F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Nov 19, 2025 21:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 137,330 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001270905-25-000003 · primary_doc.xml · derivative · entry 2 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,330 Underlying: Common Stock · 137,330 shares Expires 2035-11-17 F2 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 84,411 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001270905-25-000003 · primary_doc.xml · derivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,411 Underlying: Common Stock · 84,411 shares Expires 2035-11-17 F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:18 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001104659-25-014317 · tm256716-5_4seq1.xml · derivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-02-12 F1 · shares: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:35 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-23-035617 · doc4.xml · derivative · entry 5 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-06-05 F3 · derivative.exercise_date: This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:08 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001209191-22-032166 · doc4.xml · derivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-05-23 F1 · derivative.exercise_date: This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 12 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 27,159 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · derivative · entry 13 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799 Underlying: Common Stock · 27,159 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 401 | $506.24 | $203,002.20 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 11 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,535 | $505.49 | $1,281,407.26 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 8,989 | $504.39 | $4,533,985.08 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,254 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 9,043 | $503.61 | $4,554,137.09 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,243 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,054 | $502.77 | $2,038,220.66 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 400 | $505.01 | $202,002.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,340 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 537 | $504.14 | $270,725.17 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,740 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 300 | $502.99 | $150,897.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,277 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 200 | $504.78 | $100,956.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,577 Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 700 | $504.09 | $352,860.48 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 27,159 | $125.05 | $3,396,232.95 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,538 | $503.07 | $773,727.66 |
DisclosureSEC source: 0000914190-21-000322 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.941 to $503.315, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F3 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 999 | $481.82 | $481,338.18 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,107 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 18 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires 2028-08-06 F12 · derivative.exercise_date: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 6,080 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 17 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 Underlying: Common Stock · 6,080 shares Expires 2028-08-06 F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,556 Underlying: Common Stock · 1,556 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 22:54 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 12,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039631 · doc4.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,940 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting. Read SEC document |
| March 25, 2021 Filed Jun 9, 2023 01:35 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GiftCommon Stock | 7,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035617 · doc4.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Scott Eansor 2020 Exempt Trust Disclosed balance after: 7,142 F1 · shares: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F1 · balance_after: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F2 · balance_after: The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust. Read SEC document |
| March 25, 2021 Filed Jun 9, 2023 01:35 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GiftCommon Stock | 7,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035617 · doc4.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the John R. Eansor 2020 Exempt Trust Disclosed balance after: 7,142 F1 · shares: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F1 · balance_after: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F2 · balance_after: The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust. Read SEC document |
| March 25, 2021 Filed Jun 9, 2023 01:35 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GiftCommon Stock | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035617 · doc4.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,428 F1 · shares: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F2 · shares: The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust. F1 · balance_after: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. Read SEC document |
| March 16, 2021 Filed Jun 9, 2023 01:35 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | PurchaseCommon Stock | 14,285 | $17.50 | $249,987.50 |
DisclosureSEC source: 0001209191-23-035617 · doc4.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,713 F1 · shares: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F1 · price: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. F1 · balance_after: Reflects a 10-1 reverse stock split which became effective on January 16, 2023. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 18,819 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · derivative · entry 11 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,819 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 14,114 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · derivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,114 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,100 | $385.59 | $424,150.98 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,900 | $384.15 | $729,888.42 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,418 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,700 | $382.60 | $1,415,635.91 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,318 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,900 | $381.52 | $1,106,394.95 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,018 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 12,833 | $380.50 | $4,882,918.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,918 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,500 | $379.62 | $1,708,312.05 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,751 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,000 | $378.29 | $2,269,722.60 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 18,819 | $106.59 | $2,005,917.21 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 14,114 | $106.59 | $1,504,411.26 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs. F2 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 856 | $265.76 | $227,490.56 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 24,975 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 Underlying: Common Stock · 24,975 shares Expires 2027-08-05 F13 · derivative.exercise_date: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 24,975 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 15 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 Underlying: Common Stock · 24,975 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 15,318 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,318 Underlying: Common Stock · 15,318 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 11,488 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 13 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,488 Underlying: Common Stock · 11,488 shares Expires 2027-08-05 F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 12 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575 Underlying: Common Stock · 2,575 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.